Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282246 | 0.83 | CYP2D6 (0.45) | ALDH1A1MEN1KMT2ATSHRLMNA | |
| SCHEMBL2282269 | 0.83 | MEN1 (0.40) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2280448 | 0.78 | SLC6A4 (0.68) | CCR5 | |
| SCHEMBL2278132 | 0.73 | CCR5 (0.42) | CCR5KDM4EALDH1A1TDP1MEN1 | |
| SCHEMBL20030972 | 0.69 | USP30 (0.53) | — | |
| SCHEMBL30074461 | 0.69 | USP30 (0.51) | — | |
| SCHEMBL27171920 | 0.69 | USP30 (0.51) | — | |
| Trifluoroacetic Acid SCHEMBL5658221 | 0.69 | KDM4E (0.48) | KDM4EALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL24362344 | 0.67 | USP30 (0.56) | — | |
| SCHEMBL29599473 | 0.67 | USP30 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981909-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-9981909-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010059393-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | HTR2C, HTR2A, HTR1A | CCR5 1148/4885KDM4E 3364/4885ALDH1A1 3730/4885 |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | CCR5 1350/4885KDM4E 3468/4885ALDH1A1 3913/4885 |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR2C | CCR5 1564/4885KDM4E 4102/4885ALDH1A1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.